Clinical Trial Update: Phase IIa Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 [Phase 2]

View source ↗

Summary

A Phase IIa trial evaluating the recombinant ESAT6-CFP10 tuberculosis antigen has completed, with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tuberculosis

Drugs mentioned

• ESAT6-CFP10 recombinant protein (ESAT6-CFP10)

Snippet

Sponsor: Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Conditions: Tuberculosis | Phase 2 | Status: COMPLETED | Results posted: 2015-04-09